Efficacy of Rituximab for Remission Maintenance in Patients With Primary Angiitis of the Central Nervous System: an Open-label, Randomized, Controlled Trial Comparing Systematic Rituximab Infusions and Azathioprine

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
MAINRIPAC is a multicenter, randomized, open-label controlled clinical trial evaluating the efficacy of rituximab versus azathioprine for maintenance of remission in patients with primary angiitis of the central nervous system (PACNS). Patients are randomized 1:1 to receive either rituximab or azathioprine and are followed for 24 months, with regular clinical and brain MRI assessments to evaluate disease relapse and treatment safety.
Epistemonikos ID: c7e8fb20dbbbf50766868432a005775b3073e4d0
First added on: Oct 30, 2026